Wockhardt Equity Turnover

What does Wockhardt do? Wockhardt Ltd. generates revenue through the manufacture and marketing of pharmaceutical formulations, active pharmaceutical ingredients (APIs), and vaccines. The company produces a diverse portfolio of products across therapeutic areas including dermatology, cosmeceuticals, oncology, medical nutrition, osteoarthritis, pain management, nephrology, cough therapy, and diabetology. Key product brands sold in India include Citawok, Citawok Forte, Citawok Plus, CONSEGNA 30/70 U-200 CART, CONSEGNA R U-200 CART, DARBOTIN PFS, DECDAN, DECDAN B, DECDAN B Injection, DECDAN LITE CREAM, Emrok, Emrok O, Erliso, FOSCHEK-S, Gabawok NT, GLARITUS CART, GLARITUS DISPO, Glimaday, INOGLA, Livatira, GLARITUS CART, and VAL 450. These products are distributed through pharmaceutical channels to healthcare providers and patients in India and international markets. The company operates manufacturing and research facilities in India, the United States, the United Kingdom, and Ireland, supporting its production of sterile injectables, lyophilized products, and various dosage forms. Wockhardt's product range targets specific medical conditions, with brands like DECDAN B Injection and GLARITUS CART serving niche therapeutic needs. The firm's global presence enables it to serve both domestic and international markets with its pharmaceutical solutions. Wockhardt Ltd. focuses on delivering pharmaceutical products to healthcare professionals and patients through established distribution networks. Its therapeutic areas span from dermatology to diabetology, ensuring a broad market reach. The company's product lineup includes specialized formulations such as Emrok O and INOGLA, which cater to specific patient populations. The firm's global manufacturing footprint supports consistent supply and quality control across its product portfolio. Wockhardt is one of the most popular companies on Eulerpool.